How much funding has Nvelop Therapeutics raised?

Nvelop Therapeutics has raised $100.0M in total funding, most recently a Seed round.

Who are Nvelop Therapeutics's investors?

Nvelop Therapeutics's investors include Newpath Management, Atlas Venture, F-Prime Capital, 5AM Ventures, Cormorant Asset Management, ARCH Venture Partners.

When was Nvelop Therapeutics founded?

Nvelop Therapeutics was founded in 2022.

Where is Nvelop Therapeutics headquartered?

Nvelop Therapeutics is headquartered in Cambridge, United States.

What industry is Nvelop Therapeutics in?

Nvelop Therapeutics operates in Biotech.

How many employees does Nvelop Therapeutics have?

Nvelop Therapeutics has 51-200 employees.

Nvelop Therapeutics

nChroma

Cambridge, United States · Founded 2022 · $100.0M raised

Biotech

Headquarters: Cambridge
Employees: 51–200
Founded: 2022
Business Model: B2B

Website: nveloptx.com
Total Funding: $100.0M
Last Round: $100.0M SeedApr 2024
Rounds: 1

About

Nvelop Therapeutics (now nChroma Bio) was founded in 2022 to develop programmable, non-viral in vivo delivery systems for next-generation genetic medicines. The company combines disease-first therapeutic design with targeted delivery technologies to engineer potent and durable treatments for areas of high unmet need.

Summary

Nvelop Therapeutics is a Biotech company based in Cambridge, United States, founded in 2022. It has raised $100.0M in total across 1 round, most recently a $100.0M Seed round in Apr 2024. Investors include Newpath Management, Atlas Venture and F-Prime Capital.

LinkedIn X (Twitter)